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A B S T R A C T
Lamivudine has recently been registered for the treatment
of chronic hepatitis B patients. The main therapeutic out-
come in the studies on which the registration was based
was a drop of HBV DNA below 107 genome equivalents/ml,
the level of detection of the insensitive Abbott Genostics
assay. However, as we have reported previously, with the
use of sensitive PCR-based assays, individual differences
in virological response to lamivudine can be detected.
As a first step in analysing the chain of events after oral
intake of lamivudine we modified and validated a high-
pressure liquid chromatography (HPLC) method to evaluate
lamivudine plasma levels. Lamivudine levels in chronic
hepatitis B patients who participated in a study on the
efficacy of lamivudine were comparable to our reference
curve, which was derived from eight chronic hepatitis B
patients. From the reference curve, a mean area under the
curve (AUC) of 4994 mcg/l.h (SD 1524), a mean tmax of
42 minutes (SD 11), and a mean Cmax of 1.9 mg/l (SD 0.70)
were calculated. Lamivudine exerts its action as the active
triphosphate inside the hepatocyte after extensive handling.
Therefore, additional steps in the pharmacokinetic process
should be evaluated to explore the potential mechanisms
that are responsible for the diversity in quantitative HBV
DNA response to lamivudine.
I N T R O D U C T I O N
Lamivudine, the negative enantiomer of 2’-3’ deoxy 3’ 
thiacytidine, is a nucleoside analogue which has recently
been registered for the treatment of chronically infected
hepatitis B patients. In large phase III studies the
favourable effect of this drug was shown on suppression
of hepatitis B virus (HBV) DNA, a parameter expressing
active viral replication, which is often followed by a decline
in transaminases and improvement of liver histology.1-3
The conclusions in these studies were based on the
percentage of patients with a viral decline below the
lower limit (approximately 107 genome equivalents/ml
(geq/ml)) of the insensitive liquid hybridisation assays
(Abbott Genostics, Abbott Laboratories, Abbott Park, IL).
HBV DNA became undetectable in around 80% of patients
measured with this test after six months of therapy.1
However, if we look more carefully with more sensitive
polymerase chain reaction (PCR)-based assays, individual
differences in response to lamivudine become apparent.4,5
Whereas some patients show a rapid decline in levels even
below the threshold of the qualitative PCR assay (Roche
Monitor, lower limit of detection 400 geq/ml), in others,
the HBV continues to replicate actively even after six
months of therapy. We previously reported on a cohort of
long-term lamivudine-treated chronic hepatitis B patients
in Rotterdam.4 In the 19 patients in whom HBV DNA
was still detectable by insensitive assays (Digene, liquid
hybridisation assay, lower limit of detection 1.5 x 106 geq/ml)
after six months of therapy, only three patients had a
mutant virus that could explain this continuing active
viral replication. Thus, ongoing active replication of the
HBV must be based on some other phenomenon in the
majority of patients.
Lamivudine is subject to several transport and activation
steps from oral intake until incorporation into the
pregenomic viral chain. Our hypothesis was that poor
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uptake of lamivudine might be responsible for the sub-
optimal decline in HBV DNA in some patients. 
In order to be able to address this issue, we modified and
validated a high-pressure liquid chromatography (HPLC)
method to measure lamivudine plasma levels in chronic
hepatitis B patients. Moreover, we studied the availability
of lamivudine in blood after a standard oral dose in
chronic hepatitis B patients.
P A T I E N T S  A N D  M E T H O D S
Patients
In group A eight patients were evaluated for 24 hours after
oral intake of a single dose of lamivudine 150 mg to obtain a
lamivudine plasma reference curve. Patients fasted overnight
and blood was withdrawn over a period of 24 hours at t=0,
15, 30, 45, 60 and 90 minutes and 2, 3, 4, 6, 8, 12, 18 and
24 hours after intake of lamivudine.
In group B nine patients, in whom the viral decline during
lamivudine 150 mg therapy6 was studied in detail, the
lamivudine concentration in a serum sample taken six hours
after start of lamivudine therapy was assessed. The pharma-
cokinetic reference curve was based on plasma samples.
Therefore, the agreement between plasma and serum
results was ascertained in 11 randomly selected patients
on lamivudine who visited the outpatient clinic (group C).
High-pressure liquid chromatography of lamivudine in
plasma and serum
Lamivudine in plasma and serum was assayed with an
HPLC method slightly modified from Harker et al.7 In
short, the following procedure was used.
Sample extraction is performed using a solid-phase
extraction method (Bond Elute Verify LRC; 10 cc/130 mg,
Varian Inc., Harbor City, CA, USA), after activation of the
column with subsequently 2 ml of methanol and 2 ml of
acetic acid 1%. Next, a mixture of 1 ml of plasma and 1 ml
of acetic acid 1% is applied to the column with a pressure
of 5 mmHg for at least two minutes. The column is con-
secutively washed and dried with distilled water,
methanol/acetic acid 10% (9:1) and distilled water again.
Desorption is carried out four times with 0.5 ml of
methanol/ammonia 25% (9:1) under a low vacuum. The
four fractions are collected and evaporated to dryness
with a gentle flow of nitrogen at 40°C and subsequently
suspended in 300 l of the mobile phase by vortex-mixing.
Separation of the mixture is performed by HPLC,
equipped with a BDS Hypersil C18 column (250 x 4.6 mm
ID; 5 um), using a mixture of methanol (40 ml), acetonitrile
(5 ml), glacial acetic acid (0.5 ml), and 0.1 M ammonium
acetate in water (455 ml) as the mobile phase at a flow of
1 ml/min and at a temperature of 40°C. Quantification
was based on UV detection at 270 nm, calibrated with a
range of external standards in plasma, which were
processed the same way.
Intra- and interassay variability
Eight calibration standards of lamivudine, with a concen-
tration ranging from 0.1 mg/l to 7.5 mg/l, were analysed
simultaneously six times (intra-assay variability), expressed
as the average accuracy with percent of the deviation from
the nominal concentration. The procedure was repeated
on three separate days (interassay variability) expressed as
a co-efficient of variation.
Correlation between lamivudine levels in plasma and
serum
The concentrations of lamivudine in serum and plasma
were compared by means of a linear plot, as well as a
Bland and Altman plot.8
Modelling of pharmacokinetic data
From the 24-hour pharmacokinetic curves, the average area
under the curve (AUC), the half-life of lamivudine (t1/2),
tmax, and Cmax were calculated. Lamivudine concentrations
were fitted with the TOPFIT pharmacokinetic programme9
using a one-, two- and three-compartment model using four
weightings (1, 1/y, 1/y, and 1/y2). The Akaike criterion10
was used to establish the best fit for our data.
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Table 1
Patient characteristics
GROUP A (N=8) GROUP B (N=9) GROUP C (N=9)
Age in years (median range) 37 (17-60) 28 (22-51) 29 (17-57)
Male/female 7/1 7/2 6/3
Cirrhosis 4 1 0 (n=8)
Additional medication Patient 3: ferrofumarate Patient 4: oral Patient 1: pantoprazole
Patient 5: furosemide, aldactone contraceptive Patient 3: clinoril, cough
Patient 7: methotrexate medicine, doxazosine,
losartan, atorvastatin, insulin
Patient 4/9: paracetamol
R E S U L T S
Patient characteristics of group A, B and C are shown in
table 1. In group A, 50% of the patients had an advanced
stage of liver disease.
The lower limit of detection of the HPLC assay was deter-
mined at 0.005 mg/l and the lower limit of quantification
at 0.1 mg/l. The higher limit of detection was arbitrarily
determined at 7.5 mg/l. All calibration curves were linear
between 0.1-7.5 mg/l with a variance between -15% to +10%
in this range. A variety of drugs, which were co-administered
frequently to these patients, did not interfere with the
extraction and detection procedure.
The intra-assay variability showed an accuracy of 80 to 95%,
which is comparable with data described in the literature
(table 2).7 The interassay variability was concentration
dependent, 3 to 16.6% (table 2). Recovery of lamivudine in
spiked plasma samples compared with non-processed
standard solutions was 86% (± 6.7%).
The relation between the concentration of lamivudine in
plasma and serum was linear as observed by a line with a
slope of 0.997 and an intercept at (0.0). The Bland and
Altman plot showed a mean of the difference between the
serum and plasma level of 0.02 mg/l (SD ± 0.0411).
For group A, a mean AUC of 4994 cg/l.h (SD 1524),
a mean tmax of 42 minutes (SD 11), and a mean Cmax of
1.9 mg/l (SD 0.70) were calculated (figure 1).
If we compare the six-hour serum concentration of
lamivudine in group B (median 0.35 mg/l; range 0.28-
0.52) with the same time point in group A (median 0.32
mg/l; range 0.15-0.48), these concentrations are within
the same range.
D I S C U S S I O N
If the inhibitory effect of lamivudine on HBV replication is
studied with a sensitive PCR-based assay with a dynamic
range between 400-109 geq/ml, a wide variation in
response between individual patients is observed. In a
previous study, we showed that this could only in part be
explained by the emergence of a mutation in the catalytic
site of the polymerase gene of the HBV.4 In this study we
made a first step in further exploration of host-dependent
mechanisms which might explain the variability of
response to lamivudine.
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Table 2
Intra- and interassay variability
INTRA-ASSAY VARIABILITY INTERASSAY VARIABILITY
THEORETICAL VALUE MEAN STANDARD % COEFFICIENT MEAN STANDARD % COEFFICIENT
(MG/L) (N=6) DEVIATION OF VARIATION (N=6) DEVIATION OF VARIATION
0.1 0.096 0.009 9.4 0.094 0.016 16.6
0.21 0.189 0.009 4.8 0.19 0.018 10.0
0.56 0.495 0.022 4.4 0.487 0.026 5.4
1.04 0.875 0.013 1.5 0.882 0.043 4.9
1.53 1.293 0.018 1.4 1.296 0.05 3.9
2.18 1.819 0.11 6.0 1.884 0.102 5.4
3.24 2.583 0.037 1.4 2.69 0.13 5.0
7.5 6.177 0.18 2.9 6.22 0.18 3.0
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Figure 1
Pharmacokinetic reference curve (± 2 x SD) based on
eight chronic hepatitis B patients treated with lamivudine
150 mg once a day (group A)
The pharmacokinetic process of any drug, including
lamivudine, is characterised by a sequence of events:
absorption, distribution, metabolism and elimination.
Lamivudine is highly soluble, dissolves rapidly once in the
stomach and is absorbed in the small intestine by passive
diffusion. Food reduces the rate of absorption but not the
extent: tmax is prolonged and cmax is reduced, but the AUC is
not altered.11,12 The absolute bioavailability is reported to be
around 80%, with a mean volume of distribution of 1.3 l/kg,
indicating considerable distribution into deeper tissues.13
In chronic hepatitis B patients, lamivudine acts in the
liver, the target organ for viral replication. Lamivudine
probably enters hepatocytes through active uptake by
pyrimidine nucleoside transporters.14,15 In the cytoplasm
of the hepatocyte, lamivudine is phosphorylated to the
mono-, di- and triphosphate by deoxycytidine kinase,
cytidine monophosphate kinase and pyrimidine nucleo-
side diphosphate kinase, respectively. The diphosphate is
present in highest concentrations inside the hepatocyte
and the conversion of the diphosphate to the triphosphate
is the rate-limiting step.16 This extensive bioactivation
makes the drug prone to individual differences between
patients. Less than 10% of lamivudine is metabolised by
the liver, only 5 to 10% of lamivudine is metabolised to a
trans-sulphoxide metabolite and excreted in urine, while
around 70% of the drug is excreted unchanged in urine.17,18
In this study, we modified and validated the HPLC assay
for detection of lamivudine in plasma. Only few data on
pharmacokinetics of lamivudine in compensated chronic
hepatitis B patients have been published.18 Our pharmaco-
kinetic parameters are comparable to the published data.
Measurement of levels of lamivudine in daily practice
may be useful for two purposes. If the level is within the
normal range, this ascertains that patients have been
compliant with therapy on the one hand and that on the other
hand absorption, the first pharmacokinetic step, is adequate.
As can be observed from our data, levels of lamivudine in
plasma six hours after intake of lamivudine (group B) are
in the same range as in patients in group A at six hours.
These data, however, should be interpreted with caution,
since group characteristics may vary. Recent studies have
stressed the potential influence of co-administered drugs
on lamivudine kinetics. This is either caused by the increase
of phosphorylation of lamivudine (e.g. hydroxyurea,
methotrexate)19 or because of reduction of the excretion
ratio of lamivudine in urine (e.g. trimethoprim).20
Our kinetic data show that the lamivudine concentrations
in group B are well above the in vitro IC50 even five hours
after the maximum concentration in plasma has been
reached.16 Plasma levels have been measured after intake
of the first dose of lamivudine but these levels may
change during long-term therapy. Previous data do not
indicate that lamivudine accumulates during long-term
application, but these data ascertain sufficient levels of
lamivudine above the in vitro IC50 throughout the 24-hour
period.16 In contrast, in seven out of the eight patients in
group A of our study, levels of lamivudine 24 hours after
intake are undetectable. This may necessitate re-opening
the discussion on twice daily dosing in patients with
hepatitis B virus infection. The key question here will
be how these plasma levels relate to the levels of the
phosphorylated lamivudine inside the human hepatocytes.
Half-life of lamivudine triphosphate in human lymphocytes
infected with the human immunodeficiency virus (HIV) has
been calculated to be substantially longer (10.5-15.5 hours)
than lamivudine serum half-life.21 Conflicting data on the
half-life of lamivudine triphosphate in hepatocytes have been
published: 3.6 to 8 hours in primary duck hepatocytes22
versus 17 to 19 hours in HepG2 cell lines.16 Therefore,
research into human hepatocytes is needed both to
address the dosing issue, as well as to better understand
the differences between individual patients.
Absorption of lamivudine is a passive process and may
therefore be the least important reason for variation in
response to lamivudine between patients. In contrast,
uptake of lamivudine in hepatocytes is an energy-driven
active process, after which lamivudine is phosphorylated
inside hepatocytes. Phosphorylation is mediated by host
enzymes and the efficacy of the process from parent drug to
active triphosphate and persistence of the active triphosphate
in the hepatocyte may vary between individual patients due
to genetic polymorphism. Therefore, to be able to explain
differences in viral decline between patients infected with
the same virus, patient-to-patient differences in conversion
from lamivudine to phosphorylated lamivudine should be
explored further.
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